$HEPA preparing to advance lead drug candidate CRV431 to Phase 2 trials for the treatment of liver disease related to NASH

Ex vivo study also showing that CRV431 may work across many other tissues and organs

#biotech #stocks #NASH https://t.co/rELxxTsaBy